clinical trial · NCT04944992
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
Merck Sharp & Dohme LLC·phase2·completed·n = 145
Nonalcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisEfinopegdutide 20 mg/mLSemaglutide 1.34 mg/mL
brief summary
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
started
Aug 4, 2021
primary completion
Oct 19, 2022
completion
Oct 19, 2022
last updated
Nov 15, 2023
official title
A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol